newly inaugurated manufacturing facility in Cranbury, New Jersey, underwent a Good Manufacturing Practice (GMP) inspection by the U.S. FDA. The inspection concluded with a single observation, which Biocon plans to address within the stipulated timeframe. The company does not anticipate any impact on its business operations. The Cranbury facility, inaugurated in September, is a key part of Biocon's U.S. expansion strategy, supporting capacity expansion and supply chain efficiency. Some products are already commissioned at the site, with additional launches planned. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.